Evidence map›Paper›PMID 27659407›Full record

SynthesisDiabetes care2017

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes.

Ivan Tkáč, Itamar Raz

Registry-linked trialAbstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Diabetes care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06827002 (Cissus Quadrangularis), which is not on this map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06827002 phase1 / phase2active not recruitingstarted 2023, after this paper: background citation

Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults

Ran2023Enrolled248Registered outcomes8Posted comparisons0ConditionsAppetite Regulation, Obesity and OverweightArmsCissus quadrangularia, Dextrin, Dichrostachys glomerata, Semaglutide (Rybelsus®)
PMID 15655721PMID 23622135PMID 24323912PMID 26177483PMID 26288659PMID 28450900PMID 4337382other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ivan TkáčDepartment of Internal Medicine 4, Šafárik University, and Faculty of Medicine, Louis Pasteur University Hospital, Košice, Slovakia ivan.tkac@upjs.sk.
Itamar RazDiabetes Unit, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveData on the possible relationship of gliptin treatment with the incidence of acute pancreatitis have been controversial. The aim of the current study was to combine data on the incidence of acute pancreatitis from three large randomized controlled trials. RESEARCH DESIGN AND

methodsThree trials designed to test cardiovascular safety and efficacy of add-on treatment with a gliptin were included in the analysis, as follows: SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), and TECOS (sitagliptin). The trials included 18,238 gliptin-treated patients and 18,157 placebo-treated patients. Data were combined using a random-effects model meta-analysis.

resultsThe incidence of acute pancreatitis was significantly increased in the gliptin-treated patients when compared with the control groups (odds ratio 1.79 [95% CI 1.13-2.82], P = 0.013). The difference in the absolute risk was small (0.13%).

conclusionsTreatment with gliptins significantly increased the risk for acute pancreatitis in a combined analysis of three large controlled randomized trials.

Indexed as

Acute DiseaseAdamantaneDiabetes Mellitus, Type 2DipeptidesDipeptidyl-Peptidase IV InhibitorsHumansIncidencePancreatitisPiperidinesRandomized Controlled Trials as TopicSitagliptin PhosphateUracilAdamantanealogliptinDipeptidesDipeptidyl-Peptidase IV InhibitorsPiperidinessaxagliptinSitagliptin PhosphateUracil

Identifiers

PMID27659407

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.